Neurological Surgery 脳神経外科52巻4号

2024年07月発行

特集 髄膜腫の現在—最新の知識を活かした最善の治療のために Ⅵ 最近話題の髄膜腫の未解決問題

放射線治療が悪性転化を惹起するか

著者： 中洲敏¹

所属機関： ¹淡海医療センター脳神経外科

ページ範囲：P.839 - P.845

Point
・良性髄膜腫の悪性化は2.98/1,000 patient-yearsで起こり，頭蓋底腫瘍では頻度が低い．
・定位放射線治療後の悪性化はそれより低いが，母集団構成が異なっており比較できない．
・放射線治療に伴う二次癌や腫瘍悪性化率は，遺伝性腫瘍疾患では個別に考慮する必要がある．

参考文献

1）Sahm F, et al：Meningioma. WHO Classification of Tumours Editorial Board：WHO Classification of Tumours. 5th edition. Central Nervous System Tumours. International Agency for Research on Cancer, Lyon, 2021, pp. 283-297

2）Nakasu S, Nakasu Y：Malignant progression of diffuse low-grade gliomas：a systematic review and meta-analysis on incidence and related factors. Neurol Med Chir（Tokyo）62：177-185, 2022

3）Corniola MV, et al：Histological transformation in recurrent WHO grade I meningiomas. Sci Rep 10：11220, 2020　doi:10.1038/s41598-020-68177-x

4）Kwon SM, et al：Predictive factors for high-grade transformation in benign meningiomas. Clin Neurol Neurosurg 195：105897, 2020　doi:10.1016/j.clineuro.2020.105897

5）Nakasu S, et al：Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery：systematic review and meta-analysis of observational studies. Neurooncol Adv 2：vdaa129, 2020　doi:10.1093/noajnl/vdaa129

6）Yeon EK, et al：Clinicoradiological features of recurrent meningioma with high grade transformation. Anticancer Res 39：6299-6305, 2019

7）Louis DN, et al：Meningiomas. Kleihues P, Cavenee WK（eds.）：World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, 2000, pp. 176-189

8）Okano A, et al：Advances in molecular biological and translational studies in World Health Organization grades 2 and 3 meningiomas：a literature review. Neurol Med Chir（Tokyo）62：347-360, 2022

9）Cain SA, et al：Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression. BMC Cancer 23：216, 2023　doi:10.1186/s12885-023-10624-9

10）Williams EA, et al：Distinct genomic subclasses of high-grade/progressive meningiomas：NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun 8：171, 2020　doi:10.1186/s40478-020-01040-2

11）Ali YF, et al：Cancer risk of low dose ionizing radiation. Front Phys 8：234, 2020　doi:10.3389/fphy.2020.00234

12）Tripathi M, et al：Complications of stereotactic radiosurgery：avoidable or inevitable? Int J Neurooncol 4：S219-S234, 2021

13）Upadhyay R, et al：Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors：a systematic review and meta-analysis. Front Oncol 12：893855, 2022　doi:10.3389/fonc.2022.893855

14）Mathews JD, et al：Cancer risk in 680, 000 people exposed to computed tomography scans in childhood or adolescence：data linkage study of 11 million Australians. BMJ 346：f2360, 2013　doi:10.1136/bmj.f2360.

15）Paddick I, et al：Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery：is it time to establish a therapeutic reference level? Acta Neurochir（Wien）163：971-979, 2021

16）Musharbash FN, et al：Risk of malignant transformation of giant cell tumors of bone is 8 times lower with megavoltage vs. orthovoltage radiation therapy. Sarcoma 2022：7216296, 2022　doi:10.1155/2022/7216296

17）Evans DG, et al：Malignant transformation and new primary tumours after therapeutic radiation for benign disease：substantial risks in certain tumour prone syndromes. J Med Genet 43：289-294, 2006

18）Evans DG, et al；English Specialist NF2 Research Group：Radiation treatment of benign tumors in NF2-related-schwannomatosis：a national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression. Neurooncol Adv 5：vdad025, 2023　doi:10.1093/noajnl/vdad025

19）Mohammed N, et al：Neurofibromatosis type 2-associated meningiomas：an international multicenter study of outcomes after Gamma Knife stereotactic radiosurgery. J Neurosurg 136：109-114, 2022

20）Bin-Alamer O, et al：Stereotactic radiosurgery for vestibular schwannoma in neurofibromatosis type 2：an international multicenter case series of response and malignant transformation risk. Neurosurgery 92：934-944, 2023

21）Chen WC, et al：Radiotherapy and radiosurgery for meningiomas. Neurooncol Adv 5（Suppl 1）：i67-i83, 2023　doi:10.1093/noajnl/vdac088

22）Oya S, et al：Effect of adjuvant radiotherapy after subtotal resection for WHO grade I meningioma：a propensity score matching analysis of the Brain Tumor Registry of Japan. J Neurooncol 153：351-360, 2021

23）Gogineni VR, et al：Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett 313：64-75, 2011

24）Pinzi V, et al：Radiotherapy of meningioma：a treatment in need of radiobiological research. Int J Radiat Biol 94：621-627, 2018

25）Nakazaki K, et al：Evaluation of radiological recurrence patterns following gamma knife radiosurgery for solitary meningioma previously treated via cranial surgery. J Clin Neurosci 73：24-30, 2020

26）Seo Y, et al：Long-term outcomes after gamma knife radiosurgery for benign meningioma：a single institution's experience with 424 patients. Neurosurgery 83：1040-1049, 2018

27）Santacroce A, et al：Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery 70：32-39；discussion 39, 2012

28）Wolf A, et al：Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery：a retrospective, multicentre, cohort study. Lancet Oncol 20：159-164, 2019